Omnicell (OMCL) Stock Rating Lowered by BidaskClub

BidaskClub cut shares of Omnicell (NASDAQ:OMCL) from a hold rating to a sell rating in a research note published on Friday.

A number of other analysts have also recently commented on OMCL. Cantor Fitzgerald reaffirmed a buy rating and set a $60.00 target price on shares of Omnicell in a report on Wednesday, December 13th. Oppenheimer reaffirmed a buy rating and set a $55.00 target price on shares of Omnicell in a report on Tuesday, December 5th. Craig Hallum reaffirmed a buy rating and set a $62.00 target price (up from $52.00) on shares of Omnicell in a report on Monday, October 30th. Benchmark upped their target price on shares of Omnicell from $55.00 to $67.00 and gave the company a buy rating in a report on Tuesday, September 5th. Finally, Zacks Investment Research cut shares of Omnicell from a hold rating to a strong sell rating in a report on Wednesday, November 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $55.14.

Omnicell (OMCL) opened at $49.55 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38. Omnicell has a twelve month low of $31.85 and a twelve month high of $55.40. The firm has a market cap of $1,880.00, a P/E ratio of -450.45, a PEG ratio of 26.43 and a beta of 0.71.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, October 26th. The company reported $0.42 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The business had revenue of $186.78 million during the quarter, compared to analysts’ expectations of $192.45 million. During the same period in the prior year, the company earned $0.40 earnings per share. The firm’s revenue was up 5.7% on a year-over-year basis. analysts anticipate that Omnicell will post 0.12 EPS for the current fiscal year.

In other Omnicell news, EVP Dan S. Johnston sold 14,613 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $47.81, for a total value of $698,647.53. Following the completion of the transaction, the executive vice president now directly owns 43,621 shares in the company, valued at $2,085,520.01. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Peter J. Kuipers sold 1,926 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $51.69, for a total transaction of $99,554.94. Following the completion of the transaction, the chief financial officer now owns 40,544 shares of the company’s stock, valued at $2,095,719.36. The disclosure for this sale can be found here. Over the last quarter, insiders sold 31,090 shares of company stock valued at $1,510,221. Company insiders own 3.77% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of OMCL. Flinton Capital Management LLC boosted its position in shares of Omnicell by 74.6% during the second quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock worth $182,000 after acquiring an additional 1,802 shares during the last quarter. Riverhead Capital Management LLC boosted its position in shares of Omnicell by 76.3% during the second quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock worth $182,000 after acquiring an additional 1,830 shares during the last quarter. Sei Investments Co. boosted its position in shares of Omnicell by 36.4% during the second quarter. Sei Investments Co. now owns 4,652 shares of the company’s stock worth $200,000 after acquiring an additional 1,242 shares during the last quarter. Pinebridge Investments L.P. boosted its position in shares of Omnicell by 1.6% during the second quarter. Pinebridge Investments L.P. now owns 4,896 shares of the company’s stock worth $211,000 after acquiring an additional 76 shares during the last quarter. Finally, Amalgamated Bank bought a new position in shares of Omnicell during the second quarter worth $219,000. Institutional investors and hedge funds own 99.61% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/12/26/omnicell-omcl-stock-rating-lowered-by-bidaskclub.html.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply